US-based medical device company QT Imaging Holdings Inc (OTCQB: QTIH) revealed on Monday that it has entered into an exclusive distribution agreement with Gulf Medical Co for the supply of its FDA-cleared Breast Acoustic CT scanner and subscriptions to the QTI Cloud Platform in Saudi Arabia.
The agreement sets minimum orders of five scanners per quarter beginning in the first quarter of 2026 through to the end of 2028, totalling at least 60 scanners and generating revenue of more than USD33m. Gulf Medical will also distribute QTI's AI-enabled cloud platform, designed to enhance breast health imaging through automated classification and second-read decision support.
QTI's non-invasive 3D breast imaging technology, which avoids compression, contrast agents and radiation, is particularly relevant in Saudi Arabia where genetic predispositions, including BRCA1 and BRCA2 mutations, contribute to higher breast cancer incidence among women aged 40 to 59.
Founded in 1983, Gulf Medical Co, part of the Al-Naghi Group, is a leading distributor of medical technologies across the Middle East.
QT Imaging Holdings is a US-based medical device company focused on safe, affordable and patient-centered imaging systems using low-frequency sound waves.
Clongen Laboratories to launch sister company Clongen Pharma LLC
Curasight's uTREAT clinical trial application approved in Europe
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Citius Oncology deploys AI platform to assist commercial team ahead of LYMPHIR launch
Innovent Biologics receives approval over squamous cell lung cancer study
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer
Zelluna ASA announces Q2 2025 financial results and business update
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Agilent's MMR IHC Panel gains FDA approval as colorectal cancer companion diagnostic test
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
ANGLE partners with Myriad Genetics on circulating tumour cell DNA feasibility study
Immunovia to launch PancreaSure in US market in September with phased commercial rollout
Soligenix' dusquetide granted US FDA orphan drug designation to treat Behcet's Disease